Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
AstraZeneca said combining its Forxiga diabetes drug with Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own.
Novo Nordisk’s experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, paving the way for a bigger study on the drug’s benefits.
French drugmaker Sanofi and Google owner Alphabet’s life sciences firm Verily are to invest about $500 million in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech sectors.
Shares of Lexicon Pharmaceuticals were up more than 18 percent after the company announced its Phase III Type 1 diabetes trial met its primary endpoint.
Valeant Pharmaceuticals International Inc. was sued by buyers of its drugs, who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.
Eating a handful of nuts five times per week may reduce inflammation, a condition that contributes to heart disease, diabetes and many other chronic illnesses, say the authors of a recent U.S. study.
The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue.
New timelines were announced for a U.S. FDA decision on Iglarlixi, the fixed-ratio combination of Adlyxin (lixisenatide) and Lantus, for treating type 2 diabetes.